Taken together, our data point to a yet unknown naturally occurring mechanism to dampen CXCR4 activity in WM and the potential to translate these insights into the biology of WM into the development of promising novel therapeutic compounds in this indolent lymphoma subtype. Here, CXCR4 is linked to lymphoma.